SpectraScience (SpectraScience) Total Current Assets : $0.31 Mil (As of Sep. 2017)

View and export this data going back to . Start your Free Trial

What is SpectraScience Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. SpectraScience's total current assets for the quarter that ended in Sep. 2017 was $0.31 Mil.

SpectraScience Total Current Assets Historical Data

The historical data trend for SpectraScience's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpectraScience Total Current Assets Chart

SpectraScience Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Current Assets

Get a 7-Day Free Trial

0.65

0.80

0.86

0.53

0.36

SpectraScience Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Total Current Assets	Get a 7-Day Free Trial															0.48	0.36	0.42	0.29	0.31

SpectraScience Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

SpectraScience's Total Current Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.004	+	0.001	+	0.091	+	0.266
	=	0.36

SpectraScience's Total Current Assets for the quarter that ended in Sep. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.028	+	0	+	0.097	+	0.188
	=	0.31

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

SpectraScience (GREY:SCIE) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

SpectraScience's Liquidation Value for the quarter that ended in Sep. 2017 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.028	-	14.246	+	0.75 * 0	+	0.5 * 0.097
=	-14.17

SpectraScience Total Current Assets Related Terms

Thank you for viewing the detailed overview of SpectraScience's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

SpectraScience (SpectraScience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SpectraScience Inc (GREY:SCIE) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11568-11 Sorrento Valley Road, San Diego, CA, USA, 92121

Website

http://www.spectrascience.com

SpectraScience Inc is a US based company focused on developing the WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The firm has developed a technology platform to determine if the tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT operates by using cool, safe UV laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin treatment during the same procedure. The group sells its product in the United States and Europe, of which majority of the sales revenue is derived from the United States.

Executives

Lowell Giffhorn	officer: CFO	10875 KEMAH LANE, SAN DIEGO CA 92131
John Pappajohn	director	1660 WALT WHITMAN ROAD, SUITE 105, MELVILLE NY 11747
Euclidsr Partners, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Euclidsr Associates, L.p.	10 percent owner	45 ROCKEFELLER PLAZA, SUITE 3240, NEW YORK NY 10111
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105

SpectraScience (SpectraScience) Headlines

No Headlines